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•ABSTRACT'
 
It is well known that many plants, algae, and
 
microorganisms contain or secrete agents which may exhibit
 
anti-cancer, or cell growth modulating properties/ :: Qf
 
these', extracts from Chara alobularis Thui11. a fresh
 
water alga, may contain an agent(s) which exhibits such
 
properties. Experiments were designed to address the
 
question> does the potential growth inhibitory properties
 
of Chara. alter specific nuclear growth indicators in
 
cancerous and non-cancerous cells, and if so what might
 
this indicate about the potential mechanism of Chara
 
extract? From this question, the hypothesis that Chara
 
modulates the appearance of nuclear growth indicators
 
related to transcription and cell-cycle in Jensen sarcoma
 
but not in non-cancerous cells was derived. In this
 
study, the effects of Chara extracts were compared to a
 
well characterized anti-neoplastic agent, doxorubicin.
 
The cancerous cell line, Jensen sarcoma, which has
 
been shown sensitive to treatment with extract from Chara
 
both in vivo and in vitro, was compared to the non­
cancerous cell lines, Chang liver and (embryonic)
 
Intestine 407 cells. The effects of Chara extract and
 
doxorubicin on cells were assessed by immunefluorescence
 
using antibodies that recognize the following nuclear
 
proteins: fibrillarin, p-80 coilin, and proliferation cell
 
nuclear antigen (PCNA). Fibrillarin, a nucleolar protein
 
associated with U3 small nuclear ribonucleoprotein (snRNP)
 
and involved in rRNA processing, may provide information
 
on the integrity of nucleolar processes. P80-coilin is a
 
unique protein that is associated with nuclear structures
 
referred to as coiled bodies. Coiled bodies (CBs) are
 
most prominent in hormonally Stimulated tissues and cancer
 
cells. Their frequency has been correlated with high
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receptor levels and enhanced transcription in several
 
steroid-hormone tarqet tissues. PCNA is a cell-circle
 
dependent protein, associated with DNA polymerase delta.
 
During DNA replication, PCNA becomes associated with
 
replication sites and exhibits a granular labeling
 
pattern. Using these antibodies, information about the
 
action of the anti-neoplastic agents on transcriptional
 
and cell-cycle processes were monitored. Treatment of
 
Jensen sarcoma with 5% v/v Chara extract or 5nM
 
doxorubicin for 6 days was sufficient to alter the rate of
 
growth and reduce cell density by 50%. Similarly, the
 
rate of growth and cellular density of Intestine 407 cells
 
appeared to lowered by treatment with doxorubicin. In
 
contrast, Chara extract did not alter the rate of growth
 
of either Chang liver or Intestine 407, but did depress
 
cell density near the plateau phase.
 
Although neither Chara extract or doxorubicin seemed
 
to greatly affect nuclear structures containing
 
fibrillarin, major differences were apparent in CB
 
frequency with respect to cell type, time, and treatment.
 
In Jensen sarcoma, coiled body frequency was sharply
 
decreased after treatment with either agent, relative to
 
control cells. Chara extract did depress the CB frequency
 
in the non-cancerous cells as well, but this effect was
 
less dramatic than observed in Jensen sarcoma.
 
Additionally, the effect Chara extract on CB frequency was
 
less, compared to doxorubicin treated intestine 407 cells.
 
Assessment Of cell-cycle parameters using antibodies
 
against PCNA showed that Jensen sarcoma treated with
 
either Chara extract or doxorubicin exhibited significant
 
changes in the PCNA labeling distribution compared to
 
controls. These changes were more dramatic in Chara
 
extract treated Jensen sarcoma compared to doxorubicin.
 
Although, non-cancerous cells treated with either agent
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did exhibit some changes, these effects were not as
 
dramatiG as seen in Jensen sarcoma. Goilectively, these
 
observations revealed a complex pattern of change in
 
nuclear transcriptional and cell-cycle activitY with
 
respect to time, cell type and treatment. Additionally,
 
these observations suggests that Chara exitract does appear
 
to Contain agent(s) which exhibit a selective cytostatic
 
activity against JensCn sarcoma compared to the non­
cancerous cells.
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INTRODUCTION ,
 
In the continuing search for new drugs which exhibit
 
anti^cancer and cell growth inhibitory properties, interest
 
has increasingly focused on natural products- Extensive
 
studies along these lines have resulted in the discovery of
 
several natural compounds with promising potential, (For
 
Review: Slichenmyer and Von Hoff, 1990). Among these, Taxol,
 
isolated from Western yew bank, has received much attention
 
recently and is undergoing extensive clinical testing. Fresh
 
water algae from the genus Chara may also contain agents with
 
cancer growth inhibitory properties. What follows is a
 
review of Chara's biological properties in terms of cell
 
growth inhibition, as well as a review of literature related
 
to this project as a whole.
 
Biological Properties of Chara
 
Caballero (1919) first reported on potential
 
mosquitocidal properties of Chara after observing the absence
 
of larvae in waters where the algae bloomed. These
 
observations were subsequently confirmed and extended by
 
other investigators (Vasconcelos, 1923; Buhot, 1927) More
 
recently, the potential use of Chara in mosquito control was
 
investigated by Amonkar (1969). By utilizing organic extracts
 
from Chara. Amonkar reported iirpaired mosquito larval
 
development. Utilizing oospores from Chara in nutrient agar,
 
Harrington (1969) showed that the growth of various types of
 
bacteria could also be inhibited. The broad base inhibitory
 
action of Chara isolates was further demonstrated by Wium-

Andersen et al. (1982) They showed that two sulfur
 
compounds isolated from C. alobularis exhibited allelopathic
 
effects on phytoplankton by inhibiting photosynthesis in the
 
diatom Nitzschia palea. These inhibitory effects have also
 
been extended to mammalian systems. Su and Staba (1973)
 
reported the growth of amelanoma tumors was delayed in
 
hamsters following intramuscular injection of organic
 
extracts from Chara vulaaris. Similarly, Sherif (1980)
 
observed remission of polyoma tumors in rats after a single
 
intratumor injection of steam distillates from Chara
 
globularis. He also reported an increase in agglutination of
 
polyoma transformed, embryonic rat heart Cells, following
 
treatment with Chara. More recently, studies by Gallo
 
(personal communication) showed that steam distillates from
 
Chara globularis were capable of inhibiting the growth of
 
Jensen sarcoma tiomors in Sprague-Dawley rats following
 
intratumor injection. Along similar lines, Inman (1986),
 
utilizing organic extracts from steam distillates from Chara
 
globularis, observed a delay in growth of Jensen sarcoma and
 
rat kidney cells in vitro. Additional studies by Gallo also
 
showed that such distillates were able to retard the growth
 
of several neoplastic cell lines in vitro, including Jensen
 
sarcoma, hioman pancreas epithelioid carcinoma, and human
 
glioblastoma. In contrast, similar treatment of noinnal human
 
lung cells had no apparent growth retardation or toxic side
 
effects.
 
It is unlikely that the observed anti-neoplastic action
 
of Chara extracts is primarily attributable to toxic side
 
effects. In vivo studies with rats (Sherif, 1980) and mice
 
(Gallo, personal communication) have indicated that steam
 
distillates from Chara globularis are non-toxic to these
 
animals. For example, distillates given to mice as a
 
substitute for water for a period of three months resulted in
 
no animal deaths attributable to the extract. Su and Staba
 
(1973) assessed possible coagulant or anticoagulant
 
properties of an organic extract from Chara vulgaris.
 
They reported no changes in prothroinbin time or partial
 
thromboplastin time following intraperitbneal injections of
 
mice with the extract.
 
Only limited information is available on the identity of
 
compoxxnds present in extracts from Chara alobularis
 
(Harrington and Gallo, 1985; Anthoni et al., 1980) Two
 
classes of agents present in the mixture, undecanal and
 
various sulfur drugs are known to have anti-neoplastic
 
activities (Higaashikaze, 1981). Undecanal compouhds have
 
been shown to exhibit anti-neoplastic activities in SV40
 
virus-induced tumors in mice (Higashikaze, 1981), while
 
sulfur compounds reportedly exhibit anti-neoplastic
 
activities in vivo and in vitro (Bourgougnon et al., 1994;
 
Hensel, 1995)
 
Functional Organization of the Cell Nucleus
 
In an effort to better docviment the potential
 
anti-neoplastic properties of Chara. the present
 
investigation placed particular eitphasis on large-scale
 
nuclear changes in cells exposed to extracts from this alga.
 
What follows is a review of the major structural and
 
functional aspect of nuclear organization.
 
A. Overview of Nuclear Organization
 
Structurally the interphase nucleus can be divided into
 
several domains with specific functions (For Review: De Jong
 
et al., 1996; Spector, 1993; Brasch and Ochs 1992) which are
 
shown in figure 1. The most prominent nuclear domains
 
include the nuclear envelope, chromatin, nucleoli, and the
 
interchromatin space. The nuclear envelope helps to
 
segregate, both terrporally and spatially, major nuclear
 
processes from those in the cytoplasm.
 
Figure 1. Diagram illustrating the major components of a
 
maiiimaliah interphase nucleus. The nucleus is separated from
 
the cytoplasm by a nuclear envelope (NE), through which
 
proteins and nuclear transcripts are exported and/or imported
 
via nuclear pores (NP). The most prominent structure in the
 
nucleus is the nucleolus (Nuc) where rRNA genes are located
 
and is the site for rRNA transcription. Condensed chromatin
 
(Ch) is located primarily on the internal periphery of the
 
nucleus, with transcribed or potentially transcribed
 
chromatin looped internally. An array of structures can be
 
found within the interchromatin domain, including
 
perichrornatin granules (PG) and fibrils (PF), as well as
 
interchromatin granules (IG), small nuclear bodies (SNB) and
 
coiled bodies (CB).
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The flow of molecules between the nucleus arid the cytoplasm
 
is regulated via nuclear envelope pores. For example,
 
ribosomal subunits and mRNA molecules must exit this way
 
before coming together in the cytoplasm for protein
 
synthesis. The pores also regulate the entrance of proteins
 
and other molecules into the nucleus for structural purposes
 
and to modulate gene expression and related functions.
 
Chromatin can be grouped into two distinct domains,
 
euchromatin and heterochromatin. Euchromatin represents
 
chromosomal regions which extend into the interchromatin
 
space and contains genes which are being, or are ready to be,
 
transcribed. Heterochromatin or condensed chromatin
 
represents regions not poised for transcription at that point
 
in time, as well as telomeric and centromeric regions that
 
are linked to the nuclear envelope. All chromosomal regions,
 
however, decondense at some point in time during S-phase when
 
they replicate.
 
The nucleolus usually appears as a dominant, condensed
 
structure within the nucleus during interphase. This
 
structure can be divided into three main elements: fibrillar
 
centers, dense fibrillar coitponent, and the granular
 
component. The nucleolus is composed of various proteins,
 
like fibrillarin, silver staining nucleolar organizing
 
regions and specific chromosomal regions containing several
 
tandem repeats of genes (rDNA) coding for ribosomal RNA
 
(rRNA).
 
The interchromatin space is pervaded by an
 
interconnected network of proteins and other macromolecules
 
that may constitute a scaffold or matrix for transcription
 
and replication. Some of these components include
 
interchromatin granules, which are small nuclear
 
ribonucleoprotein (snRNP) clusters, and perichromatin
 
granules and fibrils which are usually located at the
 
periphery of chromatin, and which constitute newly
 
transcribed pre-mRNA coinplexes. .
 
Lastly, this nuclear region also contains prominent
 
structures collectively termed nuclear bodies. Nuclear
 
bodies contain a number of well defined molecular components
 
(see below) whose collective functions in these structures
 
remain unclear (For Review: Lamond and Carmo-Fonseca, 1993;
 
Brasch and Ochs, 1992).
 
B. Nuclear Bodies and Coiled Bodies
 
Nuclear bodies were first observed by Cajal (1903) in
 
neuronal cells after silver inpregnation. He referred to
 
them as "accessory bodies" due to their proximity to
 
nucleoli. Although several different morphotypes were later
 
described through electron microscopy (Bouteille et ali,
 
1982), as a group these structures appear highly conserved in
 
evolution, being found in both plants and animals (Moreno
 
Diaz de la Espina et al., 1982; Raska et al., 1991).Nuclear
 
bodies of all types seem most prevalent in hyperactive cells
 
such as cancerous tissues (Bouteille et al.,1982), virally
 
transformed cells (Jiang et al.,1991) lectin-stimulated
 
lymphocytes (Chaly et al., 1983), and hormonally stimulated
 
tissues (Vagner-Gapodano et al., 1982; Brasch and
 
Peters,1985; and Brasch et al., 1989). Stimulation of such
 
tissues generally induces an increase in the nxiiriber of
 
nuclear bodies, while absence of stimulation is followed by a
 
decline in frequency.
 
Recently the designation "coiled bodies" (CBs) has been
 
used to describe the best characterized subclass of nuclear
 
bodies (For Review: Brasch and Ochs 1992; Lamond and Carmo
 
Fonseca, 1993). The formation of CBs appear to come about
 
through nucleolar budding (Dupuy-Coiln and Bouteille, 1972;
 
Vagner-Capodano et al., 1980; Raska et al., 1990), with some
 
CBs being identified within the nucleolus of some cell lines
 
(Ochs et al., 1994).
 
The molecular composition of CBs was largely unknown
 
until the discovery of autoantibodies that specifically react
 
with nuclear antigens (For Review: Raska et al, 1991). It is
 
now known that CBs contain several specific molecular
 
components. P80-coilin is an 80Kd molecular weight protein
 
which is prevalent in all coiled body-like structures so far
 
examined (Andrade et al., 1991). The antigen appears in two
 
states, an insoluble sta:te, which forms CBs and a soluble
 
State, which exists both in the nucleus and the cytoplasm.
 
This distribution appears to be cell-cycle dependent (Andrade
 
et al., 1993), and is possibly regulated by
 
hyperphosphorylation of p80-coilin during mitosis (Carmo-

Fonseca et al., 1993).
 
The presence of fibrillarin and silver staining
 
nucleolar organizer proteins in both nucleoli and CBs
 
suggests a functional relationship may exist between these
 
two structures (Raska et al.,1990). Fibrillarin is a 34 KD
 
nucleolar protein, associated with U3 snRNP and fibrillar
 
regions of the nucleolus, which has been identified in some
 
CBs but not all (Ochs et al, 1985; and Ochs and Smetana
 
1991). The association of fibrillarin with CBs appears to be
 
greater in non-cycling cells relative to cycling cells (Raska
 
et al., 1990).
 
Another group of important proteins detected in CBs are
 
those associated with pre-mRNA splicing processes, called
 
snRNP's (Raska et al., 1991; Lamond and Carmo-Fonesca, 1993).
 
They are ubii^itous in active cell nuclei and usually appear
 
clustered in interchromatin granules and perichromatin
 
fibrils (Fakan et al., 1984). Differences in snRNP
 
distribution in nuclei from primary cell lines and
 
immortalized cells have been observed (Spector et al., 1992).
 
Immunofluorescence staining for snRNPVs in primary cell
 
lines, exhibited a broadly speckled distribution, along with
 
a small percentage of cell (2-3%) with discrete foci which
 
colocalized with GBs. In contrast, immortal REF-52 cells
 
exhibited a higher percentage (4-40%) of colocalized CB foci,
 
while adenovirus transformed REF-52 cells exhibited an even
 
higher percentage.
 
The above results confirmed and extended the long
 
standing observation that cancer and transformed cells
 
contain elevated number of CBs relative to other types of
 
tissues. The localization of snRNP's in GBs appears to be
 
transcription dependent and sensitive to heat shock,
 
actinbmycin-D, and a-amanitin, which appears to displace
 
snRNP's from coiled bodies and appears to result in increased
 
association with fibrillarin (Raska et al., 1990; Garmo-

FohseCa et al., 1992). Along with snRNP's, snRNA's have also
 
been detected in GBs by jji situ hybridization.
 
In addition to the above cortponents, several other
 
proteins have been detected in coiled bodies. These include
 
DMA topoisomerase I, M3G-capped RNA (Andrade et al, 1991;
 
Raska et al.,1991) and a protein non-snRNP splicing factor,
 
U2AF, which is an auxiliairy factor for U2 snRNP (Zamore and
 
Green, 1991). It is likely that as more specific antibodies
 
become available, additional GB-associated components will
 
also be revealed.
 
Despite containing nimierous iirportant nuclear proteins,
 
the precise function of coiled bodies is still unclear
 
(Brasch and Ochs, 1992). However, the association of GBs with
 
nucleoli in both cycling and non-cycling cells, suggests that
 
these bodies may play different functions depending on the
 
physiological state of the cell (RaSka et al., 1990).
 
For instance, the presence of various snRNP splicing factors
 
and other agents involved in RNA processing, and the presence
 
of fibrillarin and nucleolar organizing regions, iitplies that
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CBs may play a role in both pre-inRNA processing and/or
 
nucXeolU.s associated processes. Regardless of function, it
 
is clear that GBs are structural indicators of
 
transcriptional activity in nuclei where they are abundant.
 
This suggests that CBs might also be used to monitor the
 
effects of anti-neoplastic agents."
 
e. Proliferating Cell Nuclear Antigen (PCNA)
 
The use of antibodies that detect a 36 Kd nuclear
 
auxiliary protein for DNA polymerase delta, known as
 
proliferating cell nuclear antigen (PCNA), can provide
 
further information on the replicative status of cells and
 
tissues (Celis et al., 1984; Dietrich, 1993). PCNA is
 
synthesized in normally proliferating and transformed cells,
 
but is present in only very low amounts in quiescent cells.
 
Like p80-coirin, PCNA also appears to exist in two states, a
 
soluble nucleoplasmic form and an insoluble form which is
 
associated with DNA relication sites. Cells entering late G1
 
and early S-phase exhibit a immuneflucrescence pattern absent
 
in nucleolar labeling. As DNA replication proceeds, PCNA
 
becomes associated with specific nuclear structures and
 
exhibits a granular labeling pattern which appears to
 
coincide with DNA replication sites (Bravo and Macdonald-

Bravo, 1987). Completion of DNA synthesis results in a more
 
general staining pattern (Bravo and Macdonald-Bravo, 1985;
 
and Bravo, 1986). PCNA has also been implicated in DNA
 
excision repair. Cells exposed to UV irradiation exhibit
 
granular labeling which coincides with sites of repair (Celis
 
and Madison, 1986; Toschi and Bravo, 1988).
 
Therefore, PCNA may be used as a indicator of the
 
proliferation status of cells and may provide potential
 
information on the mechanism of action for anti-neoplastic
 
agents.
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METHODS
 
Project Overview
 
A. Cell Lines Characterization
 
All experimehtation for this project was planned using
 
the cancerous cell line, Jensen sarcoma (passage nvuriber
 
-100), and two nOn-cancerouS lines, Chang liver (passage
 
number —300) and (embryonic) Intestine 407 (passage number
 
-300). Jensen sarcoma was shown previously to be sensitive
 
to extracts from Chara. both in vivo and in vitro (see
 
above). The cells exhibit contact inhibition in vitro. and
 
are attachment dependent, meaning that they require a solid
 
substrate to undergo cell divisiori (Beltz, 1983). Chang
 
liver and Intestine 407 are immortalized cells by way of
 
continual passage. It is currently vinknown whether this
 
immortalization is due to an acciomulation of genetic Changes
 
in cultures or if variants initially present in the culture
 
were selected for by serial passage.
 
B. Doxorubicin
 
Doxorubicin (Adriarrycin), a well characterized
 
antibiotic used in treatment of cancers, was chosen as a
 
comparison agent for the Chara extract. Doxorubicin is a
 
broad spectrum antibiotic isolated from a strain of
 
Streotomvces oeucetius (Acromone et al., 1969). It works by
 
intercalation between base pairs in the major groove in DNA
 
(Zunino et al., 1972). This intercalation inhibits the
 
enzymes involved in DNA replication and transcription (Bachur
 
et al., 1992; Chuang and Chuang, 1979). Doxorubicin has been
 
observed to exhibit growth inhibitory activity on Chinese
 
hamster ovary cells at the microgram level with short
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exposure times as little as 1 hour (Barranco and Novak,
 
1974). With longer exposure ti^es (24 or more hours) effects
 
have been observed at the nanogram level (Bempong and Brooks,
 
1977).
 
C. Experimental Design and Goals
 
This study examines the overall question, does Chara
 
extract alter specific nuclear indicators, and if so what
 
might this indicate about the possible mechanism(s) of
 
action? Based off of this question, the hypothesis that
 
Chara modulates the appearance of nuclear growth indicators
 
related to transcription and cell-cycle in Jensen sarcoma but
 
not in non-cancerous cells was derived. To address this
 
question, several initial questions were raised and
 
appropriate experiments developed. First, does Chara extract
 
naturally contain possible anti-neoplastic agents? This
 
question was addressed by performing dose response curves in
 
Jensen sarcoma with Chara extract or doxorubicin. A dose
 
which produced an approximate 50% reduction in cell numbers
 
in Jensen sarcoma, as assessed by hemocytometer counts, was
 
chosen. The doses enployed in this study were obtained from
 
dose response curves using various concentrations of Chara
 
extract or doxorubicin (data not shown). Based on these
 
initial studies, 5% v/v Chara extract and 5nM doxorubicin
 
were chosen. 2% Chara extract or 2.5nM doxorubicin produced
 
minimal reduction (-10%) in Jensen sarcoma. A 75% reduction
 
of cell density was obtained with 10% Chara extract, while
 
lOnM doxorubicin resulted in no cellular proliferation. The
 
other cell lines were exposed to the same concentration of
 
doxorubicin and/or Chara extract chosen.
 
Once this was established, the question was raised, does
 
Chara extract alter specific nuclear indicators related to
 
transcriptional activity, and how does this effect compare to
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doxorubicin? This question was addressed through
 
immunpfluorescence microscopy using antibodies that recognize
 
p80-coilin and fibrillarin. Anti-p80-coilin was used to
 
identify and quantify coiled bodies through fluorescence
 
microscopy. Similarly, anti-fibrillarin was used to quantify
 
nucleoli and small peripheral structures. Anti-fibrillarin
 
antibodies were also used to differentiate between
 
fibrillarin positive and negative labeled CBs. Since CBs can
 
serve as indicators of nuclear and nucleolar hyperactivity
 
(Bouteille et al., 1987; Brasch and Ochs, 1992), changes in
 
their numbers can be used as broad indicators of both
 
transcriptiohal levels arid nucleolar function.
 
These microscopic Studies were accompanied by western
 
blot quantification of SDS gel^separated cellular proteins to
 
determine total cellular amounts of p80-coilin.
 
Finally, the question was asked, does Chara extract
 
alter the cyCle-cycle, and how does this effect compare to
 
doxorubicin? This question was addressed by employing
 
immunofluoreScenCe microscopy using anti-PGNA antibodies.
 
The PGNA labeling pattern was used to score the phases of 
cell division. PGNA is a nuclear protein correlated with 
proliferation of cells during the S-phase and becomes 
associated with replication sites (Bravo and Maconald-Bravo, 
1987).. . , ■ ■ ■ 
This study provides data on the effects of Ghara extract
 
on the growth of cancerous and both non-cancerous cell lines,
 
utilizing sCme very specific nuclear cortponents as indicators
 
and then by coirparing these effects to those of doxorubicin,
 
a well defined anti-neoplastic agent. In addition to the
 
questions' mentioned a,bove, several other questions are
 
addressed. 1) Does the average number of GBs vary between the
 
neoplastic cells and the non-cancerous lines, and if so what
 
might this difference mea.n? 2) What changes occur in GBs in
 
the three cell lines during proliferation? 3) If there is a
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change, what could this indicate regarding transcriptional
 
activity in relation to the growth of individual cell lines?
 
4) If fibrillarin and pSO-coilin reveal two differeht
 
populations of CBs, is there a change in these populations
 
during proliferation? 5) Does PCNA, which is an indicator of
 
cellular proliferation, differ among the three cell lines,
 
does it vary with respect to the age of the culture, and if
 
so, what might this indicate?
 
The cell enumeration data shown in this study was
 
derived from 3 independent experiments employing 3 separate
 
batches of Chara extract and doxorubicin to monitor activity
 
changes between batches. To control for possible batch
 
variations, the same batch of Chara extract and doxorubicin
 
was used in all three cell lines and includes cell
 
enumeration and all subsequent experiments. Additionally,
 
all the experiments for the three cell lines were set up
 
during the same period. Due to the variability of these
 
nuclear indicators in asynchronous cultures, at least a 100
 
cells from each cell, treatment and time period were
 
enumerated.
 
D. Experimental Analysis
 
All cell growth data, CB, fibrillarin labeled stiructure
 
covints, and nuclear PCNA pattern quantitation were arranged
 
in an a x b factorial design and subjected to analysis of
 
variance (ANOVA)(Milton and Tsokos, 1985; Dowdy and Wearden,
 
1985) using SuperAnova software (Abacuss). Data sets
 
exhibiting significant ihteraction were assessed for the
 
influence of each factor independently. Pairwise comparisons
 
were made with treatment (control. Chara and doxorubicin) apd
 
time (24,48,72,96,120... hrs.) as factors using Duncan's
 
multiple range test with Kramer's adjustment for unequal
 
sample sizes (Kramer, 1956). Coitpafisons between the cell
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types were made within the control groups with cell type
 
(Jensen sarcoma, Chang liver and Intestine 407) and time as
 
factors. To meet the assiamption of homogeneous variances
 
(homoscedasticity), the sample variances were subjected to
 
Bartlet's test. Experiment sets exhibiting significant
 
hetergenous variances were transformed using the equations
 
(y=Log e) for cell enumeration and (y=Log e+10) for p80­
coilin, fibrillarin enumeration and all data expressed as a
 
percentage. Results expressed as significant implies P<0.05
 
unless otherwise stated. All PCNA data was expressed as
 
weighted mean ± SE. The remaining data was expressed as mean
 
± SE.
 
Procedures
 
A. Cell Cultures
 
Except where indicated, all basic techniques involving
 
cell culturing follow general procedures outlined in Freshney
 
(1983). Cultures were maintained in media optimized for each
 
respective cell line as outlined by American Tissue Culture
 
Collection (ATCC). Jensen sarcoma cells (ATCC CCL45) were
 
grown in McCoy's 5A media at pH 7.4 and 5% fetal bovine serum
 
(FBS). Chang Liver cells (ATCC CCL13) and Intestine 407
 
cells (ATCC CCL6) were cultured in Basal modified Eagle's
 
(BME) media with Earle's salt solution at pH 7.4 with 10%
 
(FBS) and 15% (FBS) respectively. All cultures were
 
supplemented with 1% antibiotic-antimycotic solution
 
containing 10,000 U/ml penicillin-G, 10,000 |lg/ml
 
strepton^cin sulphate, and 25 |ig/ml of amphotericin B.
 
Culture media was buffered with lOmM sodiiam bicarbonate. All
 
cultures were maintained in a VWR Scientific model 2100
 
humidified incubator at 370C with 5% C02 - 95% air flow.
 
Stock cultures, maintained in 25 cm^ or 75 cm^ flat-bottomed
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polystyrene culture flasks were siobcultured prior to
 
confluency to maintain cells in log-phase.
 
To remove cells from the culture flask, they were
 
treated with 0.25% trypsin and ImM EDTA at 37°C for 5
 
minutes, followed by addition of fresh media and
 
centrifugation at 2,000g for 5 minutes. Cell pellets were ,
 
washed in media with FBS and centrifuged again, followed by
 
resuspension in fresh culture media. Fresh culture flasks
 
were then inoculated with cell suspension. Experimental
 
cultures were established in similar manner and then allowed
 
24 hrs to recover from trypsin treatment before exposure to
 
Chara extracts or doxorubicin (Barranco et al., 1980). All
 
cultures were replenished with fresh culture media every 48
 
hrs following treatment.
 
All cultures were grown in Corning plates or flasks
 
except where otherwise indicated. Culture reagents were
 
obtained from Gibco Laboratories, Grand Island, N.Y..
 
Culture manipulations were performed in a Labconco class II
 
vertical flow hood.
 
B. Preparation of Anti-neoplastic Agents
 
Extracts were prepared from the fresh water alga Chara
 
alobularis Thuillier. grown in a special retaining tank on
 
the CSUSB canpus. After harvesting, the material was washed
 
thoroughly with double-distilled water and then blotted dry.
 
200-400 grams of material was then placed in a stainless
 
steel juice extractor, and 50-80 ml of eluent was collected.
 
The eluent was sterile filtered (0.2|am acetate filter) and
 
frozen in 5 ml aliqubts at -80?C. Doxorubicin-HCij (Sigma)
 
solution was prepared by suspending lOmg in 10 mL of sterile
 
filtered double-distilled water (0.2 jam acetate filters).
 
Aliquots were stored at -80°C. A 100|lg/ml stock solution was
 
prepared by serial dilution and stored at 4°C.
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C. Preparation of Culture Media
 
Culture media was prepared just prior to use in the
 
following manner. Thawed Chara extract was sterile filtered
 
(0.2|jin acetate filter) to remove precipitated material which
 
could contribute to background autofluorescence. An
 
appropriate volume of extract or doxorubicin solution was
 
added to sterile filtered {0.2 |am acetate filter) incomplete
 
media, to achieve 5% v/v Chara extract or 5nM Doxorubicin.
 
The addition of FBS and antibiotic resulted in final desired
 
concentration of all media components. Control media was
 
prepared with sterile water.
 
D. Cellular Proliferation
 
An inoculum of 2ml containing 4 X 10^ cells/ml of Jensen
 
sarcoma or 5 X 10^ cells/ml of non-cancerous cell lines was
 
applied per well in 6-well (34.6mm diameter) polystyrene
 
culture plates . Cells were harvested every 24 hrs after
 
plating by exposure to 0.25% trypsin and ImM EDTA at ST^C for
 
about 5 min, followed by centrifugation at 2,000g for 5 min.
 
Cell pellets were resuspended in 1 ml of media containing
 
0.4% trypan blue (Sigma). The number of viable cells were
 
then counted using a hemocytometer. Additionally, cells were
 
enumerated by visual inspection within the cell cultures.
 
This was done by adding trypan blue to cultures and counting
 
the cells under a Nikon inverted microscope using an occular
 
grid calibrated using a micrometer.
 
E. Immunological Techniques
 
Except where indicated, all immunological techniques
 
were based on methods outlined in The American Society for
 
Cell Biology Education Committee Workshop (1992). Nunc 4­
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chamber tissue culture slides were inoculated with 0.7 ml per
 
chamber of previously mentioned cell densities. Sample
 
slides were taken at 24 hr intervals after treatment for the
 
duration of each experiment. ­
Slides were washed with lOiriM phosphate buffered saline
 
(PBS) at pH 7.4, and cells were fixed with 2% EM-grade
 
formaldehyde/PBS for 20 min at room temperature (RT). After
 
washing 3 X 10 min with PBS, the sarrple slides were stored at
 
40G in PBS. Cells were permeabilized with 0.25% Triton X-100
 
for 5 min at RT followed by a PBS wa.sh. The slides were then
 
incuba.ted for 1 hr at 37^0 in a humidified chamber, with 50|Xl
 
human antibody (AK) to PCNA (Andrade et al., 1993) or double-

labeled with rabbit antibody (R288) to p80 coilin (Andrade et
 
al., 1993) and mouse monoclonal antibody (72B9) to
 
fibrillarin (Reimer et al., 1987) at 1:200 dilution. All
 
primary antibodies were generously donated by Dr. Robert L.
 
Ochs, W.M. Keck Autoimmune Disease Center, The Scripps
 
Research Institute, LaJolla, CA. Slides were washed 3 X 10
 
min with PBS at room temperature (RT) and rinsed prior to
 
addition of 200|J.L of appropriate secondary antibodies linked
 
to FITC or rhodamine (Vector,). Samples were incubated under
 
the same conditions as the primary antibodies. Slides were
 
then again washed with PBS fpllowed by double-distilled
 
water. Coyerslips were mounted using Pluorsave
 
(Calbiochemical, La Jolla, CA) to minimize quenching of the
 
fluorescence signal.
 
Specimens were examined under 400X with a Nikon Optiphot
 
microscope equipped with phaSe contrast optics and an
 
episcopic-fluorescence attachment EF-D,containing excitatipn
 
filters B2A at 495nM for FiTC and G2A at 546nM for rhodamine.
 
Cells were photographed with a UFX-II camera system using
 
Ektachroine 400 or Fujichrome 100 slidefilm. Coiled bodies
 
were quantified directly from 35mm slides examined at
 
constant magnification in a slide projector. PCNA stained
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nuclei were scored on the basis of iitimunofluorescence
 
patterns as outlined in Bravo (1986) and Bravo and MacDonald­
Bravo(1985).
 
F. Western Blotting
 
Samples were prepared by inoculating 2bcvc? culture
 
flasks withS mL of cell suspension. After plating, cells were
 
harvested every 48 hrs by treatment with 0.25% trypsin and
 
ImM EDTA at 31'^C for 5 min. Culture media and FBS containing
 
2mM phenylmethylsulfonyl fluoride (PMSF) was then added and
 
the preparation was centrifuged 2,000g for 5min. Cell
 
pellets were resuspended and centrifuged in culture media
 
containing ImM PMSF, twice. Each pellet was resuspended with
 
an equal volume of PBS and treatment buffer (0.125M Tris-Cl
 
pH 6.8, 4% SDS, 20% glycerol, 10% 2-mercaptoethanol) to
 
attain a concentration of 2 X 10^ cells/fil as determined from
 
hemocytometer counts. Molecular weight markers were treated
 
the same way.
 
Cells were subsequently lysed by drawing the sample in
 
and out of a Hamilton syringe prior to heating at 95°C for 5
 
min followed by storage at -20°C. Samples were thawed and
 
heated at 950C for 5 minutes prior to loading 10|1L of sample
 
on a discontinuous polyacrylamide gel containing 0.1% SDS
 
(Laemmli, 1970), with the following proteins for molecular
 
weight comparison: bovine albumin (66Kd), egg albumin
 
(45Kd), glyceraldehyde 3-phosphate dehydrogenase (36Kd), and
 
carbonic anhydrase (29Kd). A 5% stacking gel and 10%
 
separating gel were used in a Bio-Rad mini-protein II
 
vertical gel apparatus. Electrophoresis was performed with a
 
0.025 M tris, 0.192 M glycine and 0.1% SDS pH 8.3 buffer at
 
15mA> set to constant current for 90 min at room temperature
 
(RT) using a Savant Instrument Inc. power supply model
 
CVR300.
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After electrophoresis, the gels and 0.2|ain nitrocellulose
 
paper (S&S NC) were prepared for electrotransfer by soaking
 
in Towbin transfer buffer for 30 min. Proteins were
 
transferred to nitrocellulose membranes in a Bio-^Rad mini-

trans blot system at SOV/gel under constant current for 2 hr
 
at 4bc. The transfer buffer was continuously mixed with a
 
magnetic stirrer.
 
Following protein transfer the nitrocellulose membranes
 
were stained with 0.5% Ponceau S stain for 30 seconds and
 
rinsed in water to determine the eveness of the transfer.
 
The nitrocellulose membranes were destained by rinsing in
 
PBS. The gels were stained 3 hr with 0.125% coomassie blue
 
R-250, 50% methanol, 10% acetic acid and destained 1 hr with
 
50% methanol, 10% acetic acid followed by 7% acetic acid and
 
5% methanol until the background was clear. Nitrocellulose
 
membranes were prepared for immunoblotting by blocking
 
membranes with 5% non-fat milk in lOOmM tris buffered saline
 
(M-TBS) at pH 7.5 for 1 hr at RT. Membranes were incubated
 
for 1 hr at 1/200 dilution in M-TBS of human antibody Shiptak
 
against p80-coilin with gentle aggitation. Membranes were
 
washed 3 X 30 minutes in M-TBS, then incubated with
 
biotinylated anti-human antibody at 1:1000 dilution in M-TBS
 
for 1 hr at RT. Membranes were then washed 3 X 10 minutes in
 
tris buffered saline at pH 7.5 (TBS) followed by incubation
 
of avidin-HRP at 1:1000 dilution in TBS for 1 hour. After
 
washing 3 X 10 minutes in TBS, membranes were colorized with
 
4-chloro-l-napthol followed by rinsing in TBS followed by
 
double-distilled water. Immunoblots were digitized and
 
relative optical densities obtained using an IS 1000 Digital
 
Imaging system (Alpha Innotech Corporation) at Loma Linda
 
University.
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RESULTS
 
Preparation of Chara Extract
 
Previous methods for the preparation of a Chara extract
 
involved collection of steam distillates derived from the
 
alga. For this study, a new method was employed for the
 
preparation of the extract. This involved direct extraction
 
of soluble agents from the alga using a juice extractor,
 
followed by filtration with 0.2|am acetate filter.
 
The final extract exhibited a light yellowish/green
 
color. Addition of 5% v/v of the Chara extract did not
 
appear to affect the pH of the culture media, since no
 
apparent change was observed with the phenol red indicator.
 
Effect of Agents on Cell Proliferation
 
Prior to treatment with anti-growth agents, the growth
 
kinetics of untreated cell lines were examined to establish a
 
control base line (figure 2). Jensen sarcoma exhibited a lag
 
period of 24 hrs following plating, prior to a noticeable
 
increase in cell density. Other cells lines exhibited
 
noticeable proliferation within the same time period.
 
The cell density of the various lines after 7 days in culture
 
varied significantly. Jensen sarcoma reached a peak density
 
of about 6.5 X 10® cells/well, while Intestine 407 and Chang
 
liver attained a density 3.5 X 10® cells/well and 2.1 XIO®
 
cells/well, respectively (figure 2).
 
The addition of 5nM doxorubicin or 5% v/v Chara extract
 
to the three cell lines markedly affected their growth
 
kinetics (figure 2). With Jensen sarcoma, treatment with
 
Chara extract resulted in a significant decrease in cell
 
density after 24 hr, while doxorubicin produced a significant
 
decrease in cell density, relative to controls, only 48 hrs
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after treatment. There were no significant
 
differences between Chara extract and doxorubicin treated
 
cells at each time point. Compared to Jensen sarcoma, Chang
 
liver and Intestine 407 responded quite differently to
 
treatment with Chara extract and doxorubicin. First, both
 
,cell lihes exhibited significant reaction to Chara treatment
 
only in the plateau growth phase, when measurable difference
 
in density were evident between 120 and 144 hrs for Intestine
 
407 and 96-144 hrs for Chang liver. Interestingly,
 
doxorxibicin significantly affected Intestine 407 cells after
 
24 hrs relative to both controls and Chara treated cultures.
 
Assessment of the growth kinetics by microscopy, shows a
 
similar behavior as seen with the hemocytometer counts
 
(Figure 3). This method of cell enumeration did, however,
 
result in a lower total cell count per well compared to the
 
hemocytometer method. This could be accounted for by the
 
knowledge that in small cultures, such as 6-well plates,
 
cells cluster at the edges of the wells. If samples are not
 
taken in such areas of the well, the cell density would be
 
underestimated.
 
Morphological Changes
 
Jensen sarcoma cells normally exhibited a spindle shaped
 
morphology during inteirphase (figure 4). However 72 hrs
 
after treatment with either Chara extract or doxorubicin,
 
marked morphological changes were evident. The cells now
 
exhibited hyperplasia along with long cytoplasmic extensions
 
(figure 4) In contrast, the cytoplasmic borders of the non­
cancerous cell lines appeared flattened and round. Treatment
 
with either doxorubicin or Chara did not appear to result in
 
an altered morphology (figure 4). ;
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Figure 2. Logarithmic growth Gurves of Jensen sarcoma.
 
Intestine 407 and Chang liver cells as assessed by trypan
 
blue exclusion following dissassociation with trypsin and
 
EDTA. Iriitial platirig densities are indicated at (P) time
 
period. While initial exposure to Chara extract and
 
doxorubicin are indicated by (T). Culture medium was
 
replaced every 48 hrs. Significant differences as assessed
 
by Diincan's multiple range test (P<0.05) are indicated as (#)
 
for untreated versus Chara treated. (*) for doxorubicin
 
treated versus untreated and (+) for Chara versus doxorubicin
 
treated cells. Data represent the meaii ± SE of 3 independent
 
experiments performed in;triplicate.
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Figure 3. Logarithmic growth curves of Jensen sarcoma,
 
Intestine 407 and Chang liver cells as assessed by trypan
 
blue exclusion. Initial plating densities are indicated at
 
(P) time period, while initial exposure to Chara extract and
 
doxoriibicin are indicated by (T). Culture medium was
 
replaced every 48 hrs. Significant differences as assessed
 
by Duncan's multiple range test (pcO.OS) are indicated as (#)
 
for untreated versus Chara treated, (*) for doxorubicin
 
treated versus untreated and (+) for Chara versus doxoriibicin
 
treated cells. Data represent the mean ± SE of 3 separate
 
areas in each well v'
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Figure 4. Phase contrast photomicrographs of control, Chara
 
extract and doxorubicin treated cells from Jensen sarcoma.
 
Intestine 407 and Chang liver cells. Magnification 1500X.
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Effects of Agents on Nuclear Indicators
 
As outlined in the introduction, the nuclear protein
 
fibrillarin is present in nucleoli, certain peri-nucleolar
 
structures and coiled bodies (CBs). However, preliminary
 
studies by Brasch et. al., (1994), using double labeling with
 
mouse monoclonal antibody (72B9) to fibrillarin and rabbit
 
antibody (R288) to p80-coilin, revealed significantly less
 
than 100% coincident labeling of GBs by the two antibodies.
 
Although all CBs appeared p80-coilin positive, not all were
 
also fibrillarin positive, suggesting that two overlapping
 
populations were present, at least operationally.
 
To investigate this possibility further and to avoid
 
ambiquity in identifying and quantifying fibrillarin and
 
coilin-containing strucutres, data from each antibody were
 
first analyzed independently.
 
A. Fibrillarin
 
Immunofluorescence localization of fibrillarin­
containing structures in Jensen sarcoma. Intestine 407 and
 
Chang liver cells by the anti-fibrillarin antibody 72B9 is
 
shown in figure 5. Comparison of phase contrast and
 
fluorescent images of the same cells (data not shown)
 
revealed that the most prominent labeled regions coincided
 
with nucleoli while CBs and other smaller labeled structures
 
appeared throughout the interchromatin domain.
 
This pattern of fibrillarin-specific labeling has been
 
widely reported in many other cells and tissues and is
 
thought to represent primarily pre-nucleolar bodies and
 
elements associated with RNA processing (Spector, 1993).
 
Despite the relatively small fluctuations with respect to
 
treatment and time (figure 6 and table 1), fibrillarin
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Figure 5. Photomicrographs of control, Chara extract and
 
doxorubicin treated cells from Jensen sarcoma, Intestine 407
 
and Chang liver cells labeled with mouse monoclonal antibody
 
72B9 against the nuclear protein fibrillarin. Nuclear
 
structures labeled with anti-fibrillarin antibody are
 
indicated by arrows. Magnification 1500X.
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Figure 6. Quantitation of fibrillarin containing nuclear
 
structures in Jensen sarcoma. Intestine 407 and Chang liver.
 
Bars with an (*) above indicate significant differences
 
between treatment groups within each time frame as assessed
 
by Duncan's multiple range test (P<0.05). Data represents
 
the mean ± SE Of 100-250 cells.
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 Table 1. Pairwise comparison of the influence of time on the
 
average number of fibrillarin labeled structures for each
 
cell tvpe within control. Chara and doxorubicin.
 
Jensen Intestine Chang 
Time Sarcoma 407 liver 
Group (Hrs) 48 72 96 120 48 72 96 120 48 72 96 120 
Con 24 S S S S S NS NS NS NS S NS NS 
Con 48 - NS NS NS - NS S S S NS NS 
Con 72 - - NS NS - - NS S - - S S 
Con 96 - - NS ■ - - NS - - - NS 
Chara 24 S NS S S S S S NS S S S NS 
Chara 48 - NS, NS NS - NS NS NS NS s S 
Chara 72 - - NS S - NS S - - NS S 
Chara 96 - - - NS - - - ,S - -■ S 
Doxo 24 s S S S ; s NS NS S 
Doxo 48 - NS s NS - NS S NS 
Doxo 72 - - NS NS - NS NS 
Doxo 96 - - - NS - - - NS 
Calculated using Duncan's multiple range test. Significant 
differences (P<0.05) between paired time points are indicated 
by (S) , while non-significant comparisons are indicated by 
(NS) . 
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distribution patterns were surprisingly unifonn and similar
 
in all three cell types. Nuclei in control Jensen sarcoma
 
Cells, typically exhibited one (or more) large fibrillarin­
rich nucleolar regions as well as smaller peripheral
 
structures and usually one distinct CB adjacent to the
 
nucleolus or within the interchromatin region. Similar
 
fibrillarin distribution was evident in Chara and doxorubicin
 
treated Jensen sarcoma, however the periphery of the
 
nucleolus appeared less irregular (figure 5). In the non­
cancerous cells, fibrillarin containing structures appeared
 
smaller and more numerous than those observed in Jensen
 
sarcoma (figure 5 and 6).
 
B. Coiled Bodies
 
As outlined in the introduction, in addition to several
 
molecules associated with pre-mRNA and rRNA processing,
 
coiled bodies are characterized by at least one luiique
 
protein, p80-coilin. Immunofluorescence localization of CBs
 
by the anti-p80-coilin antibody R288 in Jensen sarcoma.
 
Intestine 407 and Chang liver is shown in figure 7.
 
Quantitative analysis of CBs identified by R288 revealed
 
marked changes, not only with respect to cell type, but also
 
in relation to time and treatment regime (figure 8 and table
 
2). This was particularly dramatic in Jensen sarcoma.
 
Initially at 24 hrs, under all treatment conditions, an
 
average of 0.19 ± 0.05 or less CBs per nucleus was observed
 
in Jensen sarcoma cells. In control cells this value rose
 
progressively thereafter and by 72 hrs effectively all nuclei
 
contained at least 0.96 ±0.08 CB on average. This was
 
followed by a gradual decline and at confluency, an average
 
of 0.67 ± 0.07 CBs per nucleus was the norm.
 
A. significantly different pattern emerged in Jensen
 
sarcoma treated with Chara extract or doxorubicin.
 
35
 
Figure 7. Photomicrographs of control, Chara extract and
 
doxorubicin treated cells from Jensen sarcoma, Intestine 407
 
and Chang liver cells labeled with rabbit antibody R288
 
against the protein p80-coilin. p80-coilin labeled
 
structures are indicated by arrows. Magnification 1500X.
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Figure 8. Quantitation of pBO-coilin containing coiled
 
bodies in Jensen sarcoma, Intestine 407 and Chang liver.
 
Bars with an (*) indicate significant differences between
 
treatment groups within each time frame as assessed by
 
Duncan's multiple range test (P<0.05). Data represents the
 
mean ± SE of 100-250 cells.
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Table 2. Paiirwise comparison, of the influence of time on the
 
average number of p80-coilin containing structures for each
 
cell type within control, Ghara and doxorubicin.
 
Jensen Intestine Chang
 
sarcoma 407 liver
 
Time ^
 
Group (Hrs) 48 72 96. 120 48 72 96 120 48 72 96 120 
Con 24 S S S S S NS NS S NS NS s S 
Con 48 NS NS isis - NS S NS - NS S S 
Con : 72 . - NS NS - ■ - NS S. - NS S 
Con . 96 NS - - - NS > ■­ NS 
Chara 24 S S s S NS Sv S NS S S s S 
Chara 48 NS NS : . NS s s NS , - . NS s S 
Chara 72 \.­ NS :: NS - NS S s , s 
Chara 96 ■; - . V - NS ■ - - - S - ■ - - NS 
Doxo : . 24 NS NS S NS NS s s S 
Doxo 48 ■ : ;■ NS s NS s s s 
Doxo 72 . ■ s S - NS S 
Doxo 96­ - - , NS - S 
Galculated using Duncan's multiple range test. Significant
differences (P<0.05) between paired time points are indicated 
by (S), while non-significant corrparisons are indicated by 
(isrs) 
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Both agents had a significant inhibitory effect on CB
 
development, which was particularly strong with doxorubicin.
 
With both agents, the average number of GBs never exceeded
 
0.57 ± 0.06 and indeed with doxorubicin, never eixceeded 0.41
 
± 0.07 CBs per nuclei.
 
A significantly more mixed pattern of CB development was
 
evident in Intestine 407 cells (figure 8). Under control
 
conditions, the average fluctuated between 1.41 ± 0.08 and
 
2.11+0.10 CBs per nucleus for the duration of the culture.
 
The presence of Chara extract or doxorubicin did have a
 
generally negative effect on CBs average over time, but this
 
appeared far more varied than in Jensen sarcoma (figure 8 and
 
table 2).
 
Control Chang liver cells averaged the largest number of
 
CBs per nucleus of all three cell lines ranging around 2.45 ±
 
0.12 to 3.21 ± 0.16 CBs per nuclei (figure 8). A slow but
 
significant decrease in these values was evident over time,
 
an effect that was enhanced in the presence of Chara extract.
 
Remarkably, however, even at confluence the niomber of CBs
 
still averaged around 2 in this cell line.
 
C. Coiled Body Subpopulation
 
As previously mentioned, although all identifiable CBs
 
were labeled by antibodies against p80-coilin, not all those
 
bodies were recognized by the anti-fibrillarin antibody 72B9.
 
Quantitative analysis of these two CB populations revealed
 
major differences with respect to cell type, time and ahti­
neoplastic treatment (figure 9,10,11 and tables 3,4,5).
 
In Jensen sarcoma, the average number of fibrillarin
 
positive and negative CBs at 24 hrs was less than 0.2/nucleus
 
under all treatment conditions. In control Jensen sarcoma
 
the number of fibrillarin positive CBs rose significantly
 
thereafter peaking at 72 hrs with a gradual decline at
 
41
 
Figure 9. Quantitation of coiled body subpopulation in
 
Jensen sarcoma. Fibrillarin positive CBs, fibrillarin
 
negative CBs and and percentage of total CBs positive for :
 
fibrillarin. Bars with an (*) indicate significant
 
differences between treatment groups within each time frame
 
as assessed by Duncan's multiple range test (P<0.05). Data
 
represents the mean ± SE of 100-250 cells.
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Table 3. Pairwise comparison of the influence of time in
 
Jensen sarcoma within control, Chara extract and doxorubicin
 
treated cells for number of fibrillarin positive and
 
negative, p80-coilin containing structures along with % total
 
fibrillarin positive CBs.
 
Fibrillarin Fibrillarin % Total 
Positive Negative Fibrillarin 
Time CBs CBs Positive CBs 
Group (Hrs) 48 72 96 120 48 72 96 120 48 72 = 96 ,120 
Con 24 : s S S s ■ ■■ s ■ S S NS NS NS NS 
Con 48 ■ - S ^ S NS NS NS . NS . NS NS NS 
Con 72 - NS s NS NS NS NS 
Con 96 : - -r - NS - ■ - '■ NS 
Chara 24 s :V­ " S s s NS NS NS S NS NS NS NS 
Chara, 48 NS NS '":sV ■­ NS NS S NS NS NS 
Chara 72 y - ,. •/ _ NS NS NS S - NS NS 
Chara 96 S - S - • NS 
Doxo 24 NS ■ NS S NS NS NS NS NS NS NS NS NS 
Doxo 48 NS ■• ■V s ■ NS ; NS NS NS NS NS : NS 
Doxo 72 - /: S NS : - , NS NS : NS NS 
Doxo 96 - ■ ■ ■ S - NS , • ■ -■ NS 
Calculated using Duncan's multiple range test. 
differences (P<0.05) between paired time points are indicated 
by (S), while non-significant comparisons are indicated by 
(NS) . 
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Figure 10. Quantitation of coiled body subpopulation in
 
Intestine 407. CBs labeled with fibrillarin, CBs with no
 
labeling for fibrillarin, and percentage of CBs labeled with
 
fibrillarin. Bars with an (*) indicate significant
 
differences between treatment groups within each time frame
 
as assessed by Duncan's multiple range test (P<0.05). Data
 
represents the mean ± SE of 100-250 cells.
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Table 4. Pairwise comparison of the influence of time in
 
Intestine 407 within control, Chara extract and doxorubicin
 
treated cells for number of fibrillarin positive and
 
negative, p80-coilin containing structures along with % total
 
fibrillarin positive CBs.
 
Fibrillarin Fibrillarin % Total 
Positive Negative Fibrillarin 
Time CBs CBs Positive CBs 
Group (Hrs) 48 72 96 120 48 72 96 120 48 72 96 120 
Con 24 S NS S NS NS NS NS S , S NS NS NS ^ 
Con 48 - S S S - ; NS NS S - S S S 
Con 72 - S NS - - NS S - - NS ^ NS 
Con 96 - - - NS - - S • - - - NS 
Chara 24 S S s S S S NS NS S NS NS NS 
Chara 48 - NS NS NS - S S NS - NS NS NS 
Chara 72 s NS - NS S - NS NS 
Chara 96 - - - S - - S - - - NS 
Doxo 24 s S s S s s S S NS NS NS NS 
Doxo 48 
-
s s S - s s NS - NS S S 
Doxo 72 - - NS NS - - NS s - - NS NS 
Doxo 96 . - - S - - S - - - NS 
Calculated using Duncan's multiple range test. Significant
 
differences (P<0.05) between paired time points are indicated
 
by (S), while non-significant comparisons are indicated by
 
(NS).
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Figure 11. Quantitation of coiled body subpopulation in
 
Chang liver. CBs labeled with fibrillarin, CBS with no
 
labeling for fibrillarin, and percentage of CBs with
 
fibrillarin labeling. Bars with an (*) indicate significant
 
differences between treatment groups within each time frame
 
as assessed by Duncan's multiple range test (P<0.05). Data
 
represents the mean ± SE of 100-250 cells.
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Table 5. Pairwise comparison of the influence of time in
 
Chang liver within control and Chara extract treated cells 
for number of fibrillarin positive and negative, p80-coilin 
containing structures along with % total fibrillarin positive 
CBs.- ■■ '■ ■ ■ ■ 
Fibrillarin Fibrillarin % Total 
Positive Negative Fibrillarin 
Time CBs CBs Positive CBs 
Group (Hrs) 48 72 96 120 48 72 96 120 48 72 96 120 
Con . 24 NS S S S NS S S S NS S S S 
Con 48 - S s s / - S S S NS S S 
Con 72 - S s - -■ NS S , - NS S 
Con 96 - - s - - - S - - S 
Chara 24 NS NS NS s s S S S NS S S S 
Chara 48 - NS NS s - NS s S - NS s S 
Chara 72 - - NS s • - - s S . - s s 
Chara 96 - - s - - - NS - - NS 
Calculated using Duncan's multiple range test. Significant 
differences (P<0.05) between paired time points are indicated 
by (S) , while non-significant comparisons are indicated by 
(NS) . 
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confluency, while fibrillarin negative CBS reitiained constant
 
after an increase at 48 hrs (figure 9).
 
Treatment with either Chara extract or doxorubicin
 
appeared to have inhibitory effects on development in both
 
fibrillarin positive and negative CBs (figure 9). The
 
effects of doxorubicin was particularly strong on both
 
fibrillarin positive and negative CBs. while Chara's
 
inhibitory effects appeared stronger on fibrillarin negative
 
CBs as compared to those labeled with fibrillarin.
 
Even with the observed inhibitory effects of both Chara
 
and doxorubicin on fibrillarin positive and negative CBs, the
 
relative proportions of these two types of CBs appears to be
 
relatively unchanged compared to control JenSen sarcoma
 
except for a significant increase in fibrillarin positive
 
CB's at 24 hrs treated with doxorvibicin (figure 9).
 
In control Intestine 407 cells (figure 10), the pattern
 
of development for fibrillarin positive CBs was mixed over
 
time, while fibrillarin negative CBs remained fairly
 
constant. Addition of either Chara extract or doxorubicin
 
produced mixed effects on both CB types with respect to time.
 
However, assesment of the relative proportions of fibrillarin
 
positive and negative CBs remains constant between control
 
and doxorubicin treated cells, while Chara treated cells
 
exhibited a higher proportion of fibrillarin positive CBs
 
early on.
 
For both control and Chara treated Chang Liver (figure
 
11), the appearance of fibrillarin positive and the
 
proportion of fibrillarin positive CBs appeared to increase
 
with age in culture, while fibrillarin negative CBs appeared
 
to decrease with age in culture. Treatment with Chara
 
extract appeared to have only very modest inhibitory effects
 
on both fibrillarin positive and negative CB development.
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D. Western Blot Analysis
 
P80-coilin has been detected in all vertebrate cells
 
examined so far. In the present study, western blotting
 
analysis of SDS-PAGE separated polypeptides from all 3 cell
 
lines was undertaken for two reasons. First, it was
 
necessary to establish and confirm that p80-coilin was
 
present in these cells. Second, it was necessary to validate
 
independently the prescence of this protein with respect to
 
the immxmofluorescence analysis of CBs.
 
The human antibody against p80-coilin (shiptak),
 
identified a single band in western blots of SDS^PAGE
 
separated proteins in all three cell lines (figure 12).
 
Moreover, this single band was evident under all treatments
 
and time points examined as assessed by densitometric
 
analysis (table 6).
 
The densitometric analysis also suggested that
 
considerable quantitative differences in p80 content were
 
manifest not only among the three cells lines but also under
 
various treatment/growth conditions. This would have to be
 
verified, however, by repeat experiments and more rigorous
 
statistical analysis.
 
E. PCNA Quantification
 
As described in the introduction, proliferating cell
 
nuclear antigen (PCNA) can be used as an indicator of the
 
replicative status of cells. In this study three major
 
labeling patterns were observed with human antibody AK
 
against PCNA (figure 13): a) homogeneous labeling of the
 
entire nucleus, b) granular labeling throughout the nucleus,
 
and c) labeling of the nucleus excluding nucleolar regions.
 
These patterns were operationally termed homogenous, granular
 
and nucleolus-negative respectively.
 
52
 
Figure 12. Western blot using the hioman antibody Shiptak
 
against p80-coilin in Jensen sarcoma, Intestine 407 and Chang
 
liver. Control, Chara extract and doxorubicin treated cells
 
were examined, following 24, 72, and 120 hrs after treatment.
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Chara 120 Chara 120
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Control 120
Control 120
 
U1
 Chara 72
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Dox 72

Dox 72
 
Control 72 Chara 72
 
Chara 72
 
Control 72
 
Chara 24
 Control 72
 
Dox 24
 
Dox 24
 
Control 24
 
Chara 24
 
Chara 24
 
Control 24
 
Control 24
 
Table 6. Relative optical densities in western blot of p80­
coilin using the human antibody Shiptak.
 
Group Time (Hrs) Jensen sarcoma Intestine 407 Chang liver
 
- CONTROL 24	 0.75 0.92
 
CHARA	 24 0.73 0.81 0.94
 
DOX 24 0.87 0.73
 -

CONTROL 72 0.94 0.77 0.87
 
CHARA 72 ; 0.92 0.59 0.96
 
DOX 72 0.96 1.00
 -

CONTROL 120 0.99 1.00 ,
 
CHARA 120 1.00 0.74 0.99
 
DOX 120 0.74 0.82
 
-

Relative O.D. values were derived using the IS 1000 Digital
O
MC  
Imaging system by integrating00 the density area from each
 
o
band.,	 O  
55
 
Figure 13. Photomicrographs of hxjman antibody AK against
 
PCNA in untreated and treated Jensen sarcoma. Intestine 407
 
and Chang liver. The various PCNA labeling patterns observed
 
within the cells are denoted by homogenous (a), granular (b)
 
and no nucleolar labeling (c). Magnification at 1500X.
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The nucleolus-negative patterns are characteristic of cells
 
in late G1 and entering early S-phase, while granular
 
appearing cells are in active S-phase proceeding to G2 phase
 
and homogenous labeling patterns correspond to the remaining
 
portions of interphase (Bravo and Macdonald-Bravo, 1985).
 
The assesments of PCNA labeling for all times and
 
treatment conditions in Jensen sarcoma are summarized in
 
figure 14 and table 7. It is noteworthy that, overall, over
 
50% of the cells under all treatment conditions exhibited
 
nucleolus-negative staining patterns. This corresponds to
 
the late G1 and early S phase transition (Bravo and
 
Macdonald-Bravo, 1985) and remained fairly constant over
 
time. In contrast, granular (active S-phase) and homogenous
 
(G1 and G2 phase) labeling patterns varied significantly in
 
control cultures. At 24 hrs, about 5% of cells showed
 
granular patterns. This rose to over 15% at 72 hrs and
 
gradually declined as the cultures reached confluency.
 
Homogenous labeling was highest (~ 35%) at 24 hrs and at
 
confluency, with lower values in between.
 
Unlike Jensen sarcoma, intestine 407 cells exhibited
 
predominantly (50-70%) homogenous (Gl and G2) labeling ;
 
patterns at all times and under all treatment conditions
 
(figure 15 and table 8). Nuc1eo1ar-negative (Gl^ S) labeling
 
was evident in less than 30% of cells at all times.except
 
confluency, when nearly 50% of cells shared that pattern.
 
Relative to both Jensen sarcoma aind intestine 407, Chang
 
liver displayed a more even proportion of cells with either
 
homogenous (Gl and G2) or nuc1eolus-negative (Gl^ S) labeling
 
under the two treatment conditions examined (figure 16 and
 
table 9). Despite the initial gradual decline in granular
 
labeled cells in Chang liver no statistical differences were
 
observed over time with respect to both treatment conditions
 
(table 9). ■ 
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Figure 14. Quantitation of PCNA labeling in Jensen sarcoma.
 
Percentage of cells labeled with an absence of the nucleolar
 
region, percentage of cells exhibiting granular staining
 
including the nucleolus, and percentage of cells exhibiting
 
homogenous labeling. Bars with an (*) indicate significant
 
differences between treatment groups within each time frame
 
as assessed by Duncan's multiple range test (P<0.05). Data
 
represents the weighted mean ± SE of 3-8 separate fields
 
comprising 100-250 cells.
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Table 7. Pairwise comparison of the influence of time in
 
Jensen sarcoma within control, Chara extract and doxorubicin
 
treated cells for number of nucleolus-negative, granular and
 
homogenous labeled cells.
 
Nucleolus Granular Homogenous 
Time Negative 
Group (Hrs) 48 72 96 120 48 72 96 120 48 72 96 120 
Con 24 S NS NS NS S S S NS S S S NS 
Con 48 - S S S - NS NS S S S S 
Con 72 - - NS NS - - NS S - NS s 
Con 96 - - - ■ NS - S - - s 
Chara 24 NS S S S NS NS NS NS NS NS S NS 
Chara 48 - S s S - S NS NS - NS s S 
Chara 72 - - s S - NS NS - s S 
Chara 96 - - - S - - - NS - . . - - NS 
Doxo 24 S NS, NS S NS NS, ^ NS NS S NS NS . S 
Doxo 48 - S S NS ■ - NS NS NS - ,s S S 
Doxo 72 - - NS S - - NS NS - - NS S 
Doxo 96 - - - S - . - NS - - S 
Calculated using Duncan's multiple range test. Significant
 
differences (P<0.05) between paired points are indicated by
 
(S), while non-significant cortparisons are indicated by (NS)
 
61
 
Figure 15. Quantitation of PCNA labeling in Intestine 407.
 
Percentage of cells labeling with an absence of the nucleolar
 
region, percentage of cells exhibiting granular labeling
 
including the nucleolus, and percentage of cells exhibiting
 
homogenous labeling. Bars with an (*) indicate significant
 
differences between treatment groups within each time frame
 
as assessed by Duncan's multiple range test (P<0.05). Data
 
represents the weighted mean ± SE of 3-8 separate fields
 
corrprising 100-250 cells.
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Table 8. Pairwise comparison of the influence of time in
 
Intestine 407 within control. Chara extract and doxorubiciri
 
treated cells for number of nucleolus-negative, granular and
 
homogenous labeled cells.
 
Nucleolus Granular Homogenous
 
Time Negative
 
Group (Hrs) 48 72 96 120 48 72 96 120 48 72 96 120
 
Con 24 NS NS NS S NS NS NS s S S NS NS
 
Con 48 : NS NS S ' NS NS NS - NS NS S 
Con 72 NS s - NS S NS S 
Con 96 - - ■ S S 
-
NS 
Chara 24 NS NS NS S NS NS NS ; NS NS NS NS . ■' .-..s ■. 
Chara 48 . s NS NS ■ ' NS NS : NS S NS s 
Chara 72 . - NS NS : V ^ ; NS NS NS ■ S 
Chara 96 ■ ' ■ ■ S - NS : ■ • ' s 
Doxo 24 NS NS S : S s . NS NS S NS NS S NS 
Doxo 48 ■ - . NS NS . NS NS "■ S ■ ■■ s ■■■ - NS NS NS 
Doxo 12 ■ - NS / ■ s - ^ ■ - , ,NS s ■ • S NS 
Doxo 9 6 : - - s s - S: -
Calculatedusing Duncan's multiple range test. Significant 
differences (P<0.05) between paired time points are indicated 
by (S) , while non-significant coinparisons are indicated by 
(NS). „ 
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Figure 16. Quantitation of PCNA labeling in Chang liver.
 
Percentage of cells labeling with an absence of the nucleplor
 
region, percentage of cells exhibiting granular labeling
 
including the nucleolus, and percentage of cells exhibiting
 
homogenous labeling. Bars with an (*) indicate significant
 
differences between treatment groups within each time frame
 
as assessed by Duncan's multiple range test (P<0.05). Data
 
represents the weighted mean ± SE of 3-8 separate fields
 
comprising 100-250 cells.
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Table 9 Pairwise Gomparison of the influence of time iri
 
Chang liver within control and Chara extract treated cells
 
for number of nucleolULS^negative, granular and homogenous
 
'^dabeled'cells
 
Nucleolus Granular Homogenous 
Time Negative 
Group (Hrs) 48 72 96 120 48 72 96 ^ 120 48 72 96 120 
Con 24 NS NS- ^ NS NS: NS NS :; NS: NS ; NS S ' NS : S 
Con 48 - NS NS ; NS 
: 
NS NS ^NS NS NS s 
Con 72 " ■V ■ - : NS ; NS /Vv'^ NS NS NS NS 
Con 96 / S _/■ '■ ' NS : , - . NS 
Chara 24 NS ; NS : NS NS /■ s . . NS s s: , " s . S 
Chara : 48 NS NS „ y;:­ NS NS NS NS S'v. • NS 
Chara ]'\12- ■■/■ '■■■ ; ■ NS NS NS S NS 
Chara 9 6 NS NS NS 
Calculated using Duncan's multiple range test. 
differences (P,0.05) between paired time points are indicated 
by (S) , while non-significant comparisons are indicated by 
(NS) . 
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The application of Chara extract seemed to affect the overall
 
pattern of PCNA labeling most strongly in Jensen sarcoma
 
(figure 14 and table 7). This was particularly pronounced
 
with respect to granular (active S-phase) labeling where the
 
extract had a significant inhibitory effect relative to both
 
control and doxorubicin treated cultures.Somewhat
 
surprisingly, doxorubicin seemed to have a mild stimulating
 
effect in Jensen sarcoma with regard to granular labeling,
 
although this pattern was not uniform over time.
 
Despite some apparently significant differences with
 
respect treatment or time factors no consistent trends were
 
evident for controls, Chara extract or doxorubicin treatment
 
in Intestine 407 or Chang liver. Indeed. Chara extract had
 
virtually no effect on PCNA labling in Chang liver and very
 
little in Intestine 407 compared to controls.
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DISCUSSION
 
The primary focus of this investigation was to further
 
examine the effects of an extract from the alga Chara
 
alobularis on the growth of cancerous and non-cancerous cells
 
in culture. The approach taken was to corrpare the effects of
 
such extracts relative to those of the well characterized
 
anti-neoplastic agent, doxorubicin. Several cell cycle and
 
transcription-related indicators were monitored for this
 
purpose, including cell morphology, growth kinetics, the
 
appearance of coiled bodies, nucleoli and PCNA labeling.
 
These parameters were examined in relation to cell type, time
 
in culture and treatment with anti-neoplastic agents.
 
Cell Proliferation and Morphology
 
The results of the present investigation clearly
 
demonstrated that addition of 5% v/v Chara extract markedly
 
inhibited the growth of Jensen sarcoma cells in culture.
 
Indeed, the extract appeared to be both more effective and
 
selective in this regard than 5nM doxorubicin.
 
For example, not only was inhibition of Jensen sarcoma by
 
Chara extract faster than doxorubicin (24 vs 48 hrs after
 
treatment), it was also less pronounced than doxorubicin in
 
the non-cancerous, intestine 407 cells. Collectively,
 
therefore, these results strongly support previous reports
 
(Gallo, personal communication; Sherif, 1980) that the alga
 
Ghara contains coirpounds with anti-neoplastic properties
 
Application of Chara extract did significantly affect
 
cell density at the plateau phase in the two non-cancerous
 
cell lines, though far less dramatically than Jensen sarcoma.
 
This may well reflect cytotoxic activity resulting from
 
accumulation of extract-derived, secondary metabolites that
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only reached critical concentrations as the cultures
 
approached confluence (Dolfini et al, 1973).
 
Vtoile Chara extracts appeared to preferentially inhibit
 
growth of Jensen sarcoma, doxorubicin inhibited the growth of
 
both Jensen sarcoma and Intestine 407. This observed action
 
by doxorubicin on both cancerous and non-cancerous cells has
 
also been reported in other studies (Tidefelt et al.,.1991).
 
Although the precise reason for this is unclear, doxorubicin
 
may have a broad spectrum inhibitory action on cell growth
 
compared to Chara extract.
 
Unlike the non-cancerous cells which did not exhibit any
 
gross alterations in morphology following prolonged treatment
 
with either Chara extract or doxorubicin, Jensen sarcoma
 
cells exhibited hyperplasia along with an increase in
 
cytoplasmic extensions. Such gross changes in morphology in
 
cancerous cells may be a prelude to eventual resistance
 
against anti-neoplastic agents, through induced
 
differentiation at the nuclear, cytoplasmic, or membrane
 
levels.
 
There are niomerous reports in the literature that cancer
 
cells resistant to anti-neoplastic agents exhibit one or more
 
of the following characteristics: a) differentiated
 
morphology due to changes in expression of adhesion and
 
membrane proteins, b) increased expression of P-glycoprotein
 
which is involved in the efflux of drugs from the
 
intracellular region, c) slower rates of growth, and d)
 
increased expression Of enzymes involved in the metabolism of
 
anti-neoplastic agents such as glutathione-S-transferase
 
(Gibelli et al., 1994; Rasbridge et al., 1994; Choa et al.,
 
1992). Agents have also been found that can redirect
 
cellular differentiation by binding to actin and inducing
 
polymerization or stabilization of pre-existing actin
 
filaments (Bubb et al., 1994). Amine oxides reportedly
 
induce changes in molecular organization, osmotic and
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permeabilitY characteristics of cell membranes (Miko and
 
Devinsky 1992), and retinoids have been found to modulate
 
gene expression by binding to RAR chromosome sites (Pemrick
 
et al., 1994).
 
Fibrillarin Containing Structures
 
Despite significant changes in CB frequency and PCNA
 
staining patterns (see discussion below), nucleolar
 
components as revealed by immunfluorescence labeling with
 
anti-fibrillarin antibody 72B9, remained comparatively
 
stable. This overall uniformity was evident among all three
 
cell lines, both in terms of treatment regime and age in
 
cultures. Since fibrillarin is a major structural protein of
 
pre-nucleolar bodies and nucleoli (Oches et al., 1985;
 
Spector, 1993) these observations indicate that the
 
structural integrity of these key nuclear domains was
 
relatively unaffected by the diverse growth and treatment
 
conditions utilized in this investigation. However, it
 
remains unclear whether such stability also expanded to the
 
functional aspects of these domains, namely rRNA metabolism
 
and pre-ribosome production.
 
Any nijmerical and morphological assesment of fibrillarin
 
containing nuclear structures based on light microscopy is
 
clearly limited in resolution and should be extended to the
 
electron microscope level. Moreover, inclusion of all
 
fibrillarin positive elements in this analysis (pre-nucleolar
 
bodies, nucleoli, GBs and other smaller components), could
 
well mask time and/or treatment effects on each individual
 
structure. That was certainly the case with respect to
 
fibrillarin negative CBs (see discussion belpw), but it is
 
also known that the size and shape of nucleoli vary with
 
respect to the cell-cycle. During Gl, nucleoli are
 
characterized as small segregate structures possibly
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coalescing into larger more prominent nucleoli during G2
 
(Spector, 1993). Such effects may not have been as
 
pronounced in the present study which utilized asynchronous
 
cells.
 
In the present study, the apparent absence of major
 
structural effects on fibrillarin containing nuclear
 
structures in terms of treatmient could indicate that rRNA
 
transcription was insensitive to the concentrations of Chara
 
extract or doxorubicin employed. For example,
 
immunofluorescent labeling of cells treated with the
 
transcriptional inhibitors, actinomycin D or 5,6-dichloro-l­
beta-d-ribo furanosyl benzimidazole which selectively block
 
rRNA production, induced segregation of nucleoli into remnant
 
structures (Raska et al, 1990), That was clearly not
 
observed here. Along related lines, while RNA polymerase II
 
and III have been shown to be sensitive to doxorubicin
 
treatment (Chaung and Chuang, 1979 and Logan and Ackerman,
 
1988), RNA polymerase I, which is responsible for rRNA
 
transcription, appears to be insentive to this agent at
 
micromolar concentrations (Wassermann et al, 1988).
 
Nonetheless, doxorubicin can induce nucleolar segregation at
 
relatively high micromolar concentrations (Abe et al, 1996),
 
indicating that its precise mode of action in this regard
 
remains to be determined.
 
Coiled Bodies and Cell-Cyde
 
The results of the present investigation are in general
 
accord with many previous studies on cells in cultures. (For
 
Review: Brasch and Ochs, 1992; Lamond and Carmo-Fonseca,
 
1993), showing that CB niombers can vary in relation to growth
 
and metabolic rates and stages of the cell-cycle. Beyond
 
that, however, significant differences were observed among
 
the three cell lines utilized here. Not only were the
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absolute niiiribers of CBs different, lowest in Jensen sarcoma
 
and highest in Chang liver, but their relative frequency over;
 
time also varied significantly. For example, in Jensen
 
sarcoma control cultures, only an average of two cells in ten
 
displayed CBs at 24 hrs, while at 72-96 hrs virtually all
 
cells did. In sharp contrast, Chang liver averaged 2.4-3.2
 
CBs for the duration and intestine 407 values were
 
intermediate. Since the accompanying western blot data did
 
not reveal comparable quantitative differences in total cell
 
p80-coilin levels, the observed differences in both absolute
 
and relative CB numbers must be due to, as yet, unknown
 
causes. a 'v ■ 
An unexpected and potentially very interesting
 
correlation emerged when CB nxjmber changes and PCNA labeling
 
patterns were compared. For all three control cultures, the
 
pattern of CB development over time, appeared to parallel
 
most closely the development of nuclei exhibiting granular
 
labeling which corresponds to those active in DNA synthesis
 
(Bravo and Macdonal-Bravo,1985). This does not imply that
 
more CBs developed during S-phase compared to either G1 or
 
G2, since this study utilized asynchronous cultures.
 
Actually the opposite is observed in synchronous cultures
 
where cells in S-phase exhibit the fewest CBs compared to G1
 
or G2 (Andrade et al, 1991).
 
The addition of Chara extract to the non-cancerous cells
 
did appear to depress CB development slightly, particularly
 
in Chang liver during periods of logarithmic growth and near
 
plateau, while not altering the relative proportion of
 
various PCNA labeling patterns compared to controls. This
 
suggests that Chara extract did slightly modify the
 
transcriptional state of the non-cancerous cells, independent
 
of changes in proliferation. The reason for these decreases
 
is unknown, but could reflect interference in a signal
 
transduction pathway regulating transcription or the
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transcriptional process itself. For example, extracts from
 
wheat germ have been shown to interfere with RNA polymerase
 
III activity in yeast (Furter and Hall, 1991), while extracts
 
from Koelreutera henrvi and Polvaon\jm cusoidatxjm have been
 
observed to alter protein kinase activity (Chang et al.,
 
1996). Alternatively, the observed depression in CB
 
development may not be due to the extract itself, but a
 
possible accumulation of secondary metabolites as mentioned
 
previously which may be affecting the cell density attained
 
by the non-cancerous cells.
 
While Chara extract appeared to exhibit little effect on
 
the cell-cycle of the non-cancerous cells, it had a dramatic
 
effect in Jensen sarcoma. For example, the significant
 
increase of Jensen sarcoma cells exhibiting no nucleolar
 
labeling along with the significant decreases of cells with
 
granular or homogenous labeling, suggests that the extract
 
was blocking cells at the late Gl or early S-phase. This
 
accumulation of cells exhibiting one PCNA labeling pattern
 
has been seen with drugs such as hydroxyurea that block S-

phase initiation and this results in an increased number of
 
cells exhibiting no nucleolar labeling (Bravo and MacDonald-

Bravo, 1985). Thus, the decreases seen in CB numbers in
 
Chara treated Jensen sarcoma corrpared to controls, may be a
 
reflection of a decreased rate of proliferation, as assessed
 
by a decrease in the proportion of cells exhibiting granular
 
labeling. However, other effects of Chara extract on
 
transcription, such as those previously mentioned for the
 
non-cancerous cells, may also be involved.
 
The addition of doxorubicih resulted in dramatic
 
decreases in CB development in Jensen sarcoma and modest
 
changes in Intestine 407, while altering the appearance of
 
granular labeled Jensen sarcoma and slightly altering them in
 
intestine 407. These decreases in CB development suggest
 
that doxorubicin may be interfering with the transcriptional
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process by intercalating within the major groove of DNA,
 
thus, inhibiting RNA polymerase (Logan et al., 1989).
 
However, while doxorubicin depressed CB development in Jensen
 
sarcoma, it appeared to increase the proportion of cells
 
exhibiting a granular labeling pattern compared to control
 
Jensen sarcoma. Therefore, the intercalation of doxorubicin
 
within the DNA may also result in a delay in the progression
 
of DNA synthesis, for example, by inhibiting the helicase
 
progression (Bachur et al., 1992). However the absence of a
 
decrease of homogenously labeled cells representing G1 and G2
 
phase, suggests that this might not be the case. Instead
 
these increases in granular labeled Jensen sarcoma may be a
 
reflection of increased association of PCNA with DNA repair
 
sites due to DNA damage induced by doxorubicin (Celis and
 
Madison, 1986; Toschi and Bravo, 1988). In, contrast to
 
Jensen sarcoma, doxorubicin treated Intestine 407 exhibited
 
an initial decrease in the proportion of cells in active S-

phase. In conjunction with the decrease and shift in CB
 
development over time, doxorubicin may also have exerted an
 
initial cytotoxic effect on intestine 407.
 
A surprising observation was that Jensen sarcoma cells
 
exhibited a high proportion of no nucleolar PCNA labeling,
 
while Intestine 407 exhibited the highest proportion of
 
homogenous labeling and Chang liver appeared to be fairly
 
evenly mixed between the homogenous and no nucleolar
 
labeling. The significance for these differences is unknown,
 
but they may reflect changes in the stages of transformation
 
from normal to,cancerous cells. The cancerous Jensen sarcoma
 
cells may be primed for entering DNA synthesis phase by
 
having cells at the late Gl and early S-phase, while the non­
cancerous cells are set to maintain their status in either G2
 
or ,mdre likely, Gl. These differences in the proportion of
 
cells exhibiting various PCNA labeling patterns could be
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explained by variations in the duration of each part of the
 
cell-cycle (Takahashi et al., 1995).
 
A major and somewhat unexpected finding in the present
 
study was the presence of two distinct populations of CBs,
 
one containing and one apparently lacking fibrillarin. This
 
was revealed by double-labeling experiments using antibodies
 
against both p80-coilin and fibrillarin. While it is
 
possible that these "fibrillarin-negative" CBs are truly
 
devoid of this protein, it is more likely that the
 
appropriate fibrillarin epitope was inaccessable to the anti­
fibrillarin antibody 72B9. Either way, this might indicate a
 
structural or conformational difference reflective of two
 
distinct CB sub-populations. Whether this also indicates
 
possible functional differences between the two types of CBs,
 
and thereby account for their observed differences in
 
behavior in all cell cultures with respect to time and
 
treatment regime, is as yet unclear.
 
The association Of fibrillarin with CBs has been
 
reported before and has suggested a possible functional
 
relationship between nucleoli and CBs (Raska et al., 1990;
 
Raska et al., 1991; Ochs et al., 1994). The significance of
 
these two possible classes of CBs is unknown, however they
 
may represent respective changes in nucleolar and
 
extranucleolar gene expression (Malatesta et al., 1994).
 
The addition of either doxorubicin or Chara extract had
 
a generally negative effect on both classes of CBs in Jensen
 
sarcoma. In Intestine 407, addition of Chara extract appeared
 
to affect CBs more negatively lacking fibrillarin, while
 
doxorubicin had a mixed effect. In Chang liver, addition of
 
Chara extract appeared to have a more negative effect pn
 
fibrillarin positive cells compared to those without
 
detectable fibrillarin, particularly as the cells approach
 
confluency.
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A unique observation about the proportion of
 
"fibrillarin-positive" and "fibrillarin-negative" CBs was
 
made (figure 8,9 and 10). For the most part, in all of the
 
cell lines, the proportion of these two CB subpopulations
 
appears to be insensitive to drug exposure with either Chara
 
or doxorubicin when using the concentrations employed. This
 
suggests that the relative proportion of these two classes of
 
CBs within the mammalian nucleus may be tightly regulated.
 
The functional significance of the two CB subpopulations
 
and their apparent differences relative to treatment with
 
Chara extract and doxorubicin remains unclear. Carmo-Fonseca
 
et al. (1992) have shown a decreased association of snRNP's
 
in CBs, while the assocation of fibrillarin with CBs
 
increases, in Hela cells treated with a-amanitin or heat
 
shock. The change observed here may be similar in nature.
 
Additional Modes of Action for Chara extract Components
 
In Jensen sarcoma, Chara extracts appeared to be
 
altering CB niombers by influencing cell-cycle behaviors,
 
compared to doxorubicin which appeared to be directly potent
 
on CB development by inhibiting transcription. The data from
 
this study suggest that Chara extract exert its action by
 
blocking or delaying the cells progression through late G1 or
 
early S-phase as assessed by PCNA labeling (Bhuyan et al.,
 
1972). This observed action may be exerted by changes
 
related to the membrane or cytoskeleton. In the alga Chara.
 
the internal space of antheridial cells become filled with
 
polysaccharides (Gosek and Kwiatkowska, 1993; Gosek and
 
Kwiatkowska, 1991). These polysaccharides could bind to
 
specific membrane proteins which are e3<pressed in neoplastic
 
cells but expressed at a low level or not at all in non­
cancerous cells. The result would be to increase the
 
adhesiveness of the cells or block activiation of membrane
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bound receptors (Boyd and Read, 1988). In recent years, algal
 
polysaccharides have been shown to represent an important
 
class of products which exhibit various antitumor,
 
anticoagulant, antithrombotic and antiviral activity (For
 
review: Wong et al., 1994; Lincoln et al., 1991). The
 
action of Chara extract may be similar to that seen by
 
sulfated polysaccharides from Ascoohvllimi nodosum. which
 
block non-small-cell bronchopulmonary carcinoma in the G1
 
phase (Riou et al, 1996), Similarily, Chara contains
 
profilins which are actin binding proteins that help regulate
 
the polymerization of actin. These profilins have been shown
 
to exhibit a high homology with plant profilins which have
 
been shown to bind to actin in cardiac muscle (Ruhlandt et
 
al., 1994), thus a potentially interfering with cytoskeletal
 
arrangements. Either one of these mechanisms could cause a
 
decreased rate of proliferation and ,thus, a corresponding
 
decrease in rate of transcription resulting in a decrease in
 
CB development. This is, however, assuming that only a
 
single agent is responsible for the observed action of Chara
 
on the growth of Jensen sarcoma in vitro and in vivo.
 
Possible additive or synergistic effects between various
 
agents could play a role as well. Either way, the data do
 
appear to show that Chara naturally contains agents which
 
exhibit fairly selective growth inhibitory properties.
 
Conclusion
 
This study does show that Chara alobularis contains
 
conpounds which exhibit fairly selective anti-neoplastiC
 
activity. The approach to assess Chara's potential anti-

neoplastic activity is unique, however, the approach does
 
look at two factors which are usually altered in cancer
 
cells, trancscription and cell-cycle. This approach also
 
provided additional insight into the nature of nuclear
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organisation and how it is influenced by age in culture and
 
growth inhibitors. Additional experiments are required to
 
fractionate the extract in order to illucidate the actual
 
agent(s) involved. However, it is speculated that the active
 
agent in Chara globularis is a type of polysaccharide. Such
 
anti-cancer agents may provide new approaches in treating
 
cancer, since convential means usually carry undersirable
 
side effects. Polysaccharides are water soluble and easily
 
administered. In addition they have not been found to induce
 
mutagenic or carcinogenic effects (Wagner. 1985). Bioactive
 
polysaccharides from algae have also been shown to induce the
 
production of various anti-tumor cytokines with less severe
 
side effects associated with direct administration of
 
recombinant cytokines (Lenk et al. 1989). Besides cytokine
 
production, these polysaccharides have been shown to
 
stimulate various immune cells as well. Future knowledge of
 
the structural conformation of such compounds may also help
 
lead to the development of more potent and specific compounds
 
in the treatment of cancer.
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